Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55,705,828
-
Total 13F shares
-
19,088,635
-
Share change
-
+940,458
-
Total reported value
-
$370,127,115
-
Put/Call ratio
-
145%
-
Price per share
-
$19.39
-
Number of holders
-
87
-
Value change
-
+$23,864,503
-
Number of buys
-
53
-
Number of sells
-
36
Institutional Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q4 2020
As of 31 Dec 2020,
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,088,635 shares.
The largest 10 holders included
Aquilo Capital Management, LLC, BVF INC/IL, BlackRock Inc., Atlas Venture Associates IX, LLC, Atlas Venture Associates IX, LLC, Rock Springs Capital Management LP, VANGUARD GROUP INC, Alphabet Inc., Novo Holdings A/S, and Artal Group S.A..
This page lists
87
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.